Who
Shannon L. Devers
EVP, Chief Human Resources Ofc
Company insider
Files Form 4 as: EVP, Chief Human Resources Ofc, Ionis Pharmaceuticals.
In numbers
- Trades disclosed
- 97
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $15.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 29 Sep 2024
- Last trade
- 16 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Oct 2026filed 19 Oct 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $59K1,357 at $43.54 | filing |
| 15 Oct 2026filed 19 Oct 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,820 at $0.00 | filing |
| 15 Oct 2026filed 19 Oct 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,820 at $0.00 | filing |
| 2 Apr 2026filed 2 Apr 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $459K6,193 at $74.05 | filing |
| 2 Apr 2026filed 2 Apr 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $459K6,193 at $74.05 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $132K3,510 at $37.58 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,510 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,760 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —385 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $154K3,760 at $40.85 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $191K5,500 at $34.69 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,951 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,510 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,760 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —385 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $227K6,951 at $32.60 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $20K385 at $52.87 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M14,321 at $79.12 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Shannon L. Devers; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.